Evaluation of apoptogenic adenovirus type 5 oncolytic vectors in a Syrian hamster head and neck cancer model

Cancer Gene Therapy

Volumn 21, Issue 6, 2014, Pages 228-237

  Vijayalingam, S ^a   Kuppuswamy, M ^a   Subramanian, T ^a   Strebeck, F F ^a   West, C L ^a   Varvares, M ^b   Chinnadurai, G ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ADENOVIRUS TYPE 5 ONCOLYTIC VECTOR; ADENOVIRUS VECTOR; CASPASE 3; DIMETHYLBENZ[A]ANTHRACENE; E1B PROTEIN; ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL TRANSPLANTATION; CHEEK POUCH; DRUG EFFECT; DRUG SCREENING; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; MALE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SYRIAN HAMSTER; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; TUMOR XENOGRAFT; VIRUS FIBER; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; GENE VECTOR; GENETICS; HEAD AND NECK TUMOR; HUMAN ADENOVIRUS C; MESOCRICETUS; METABOLISM; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALIA; CRICETINAE; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 5; MESOCRICETUS AURATUS;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADENOVIRUS E1B PROTEINS; ADENOVIRUSES, HUMAN; ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; MALE; MESOCRICETUS; MICE, NUDE; ONCOLYTIC VIROTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903599708     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2014.22     Document Type: Article

References (43)

1. Ries L, Young J, Keel G, Eisner M, Lin Y, Horner M. SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program 1998-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program; NIH Pub. No. 07-6215: Bethesda, MD, 2007.
2. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-1940.
3. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
4. Baselga J, Schoffski P, Rojo F, Dumez H, Ramos FJ, Macarulla T et al. A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24: 122s-122s.
5. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24: 2666-2672.
6. Reuter CW, Morgan MA, Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 2007; 96: 408-416.
7. Sharma H, Sen S, Lo Muzio L, Mariggio A, Singh N. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther 2005; 4: 720-727.
8. Bauer JA, Trask DK, Kumar B, Los G, Castro J, Lee JS et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther 2005; 4: 1096-1104.
9. Vijayalingam S, Subramanian T, Ryerse J, Varvares M, Chinnadurai G. Down-regulation of multiple cell survival proteins in head and neck cancer cells by an apoptogenic mutant of adenovirus type 5. Virology 2009; 392: 62-72.
10. Blackford AN, Grand RJ. Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation. J Virol 2009; 83: 4000-4012.
11. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611-623.
12. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
13. Chia MC, Shi W, Li JH, Sanchez O, Strathdee CA, Huang D et al. A conditionally replicating adenovirus for nasopharyngeal carcinoma gene therapy. Mol Ther 2004; 9: 804-817.
14. Toivonen R, Suominen E, Grenman R, Savontaus M. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer. Oncol Rep 2009; 21: 165-171.
15. Blackwell JL, Miller CR, Douglas JT, Li H, Reynolds PN, Carroll WR et al. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1999; 125: 856-863.
16. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993; 53: 4477-4480.
17. Pan JJ, Zhang SW, Chen CB, Xiao SW, Sun Y, Liu CQ et al. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27: 799-804.
18. Nemunaitis J. Head and neck cancer: response to p53-based therapeutics. Head Neck 2011; 33: 131-134.
19. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016-1027.
20. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270-1276.
21. Bortolanza S, Alzuguren P, Bunuales M, Qian C, Prieto J, Hernandez-Alcoceba R. Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters. Hum Gene Ther 2007; 18: 681-690.
22. Hasegawa N, Abei M, Yokoyama KK, Fukuda K, Seo E, Kawashima R et al. Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters. Int J Cancer 2013; 133: 1479-1488.
23. Spencer JF, Sagartz JE, Wold WS, Toth K. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster. Cancer Gene Ther 2009; 16: 912-922.
24. Adams J, Heintz P, Gross N, Andersen P, Everts E, Wax M et al. Acid/pepsin promotion of carcinogenesis in the hamster cheek pouch. Arch Otolaryngol Head Neck Surg 2000; 126: 405-409.
25. Manoharan S, Balakrishnan S, Menon VP, Alias LM, Reena AR. Chemopreventive efficacy of curcumin and piperine during 7,12-dimethylbenz[a] anthraceneinduced hamster buccal pouch carcinogenesis. Singapore Med J 2009; 50: 139-146.
26. Min BM, Kim K, Cherrick HM, Park NH. Three cell lines from hamster buccal pouch tumors induced by topical 7,12-dimethylbenz(a)anthracene, alone or in conjunction with herpes simplex virus inoculation. In Vitro Cell Dev Biol 1991; 27A: 128-136.
27. Subramanian T, Vijayalingam S, Chinnadurai G. Genetic identification of adenovirus type 5 genes that influence viral spread. J Virol 2006; 80: 2000-2012.
28. Gonzalez R, Huang W, Finnen R, Bragg C, Flint SJ. Adenovirus E1B 55-kilodalton protein is required for both regulation of mRNA export and efficient entry into the late phase of infection in normal human fibroblasts. J Virol 2006; 80: 964-974.
29. Slaga TJ, Gimenez-Conti IB. An animal model for oral cancer. J Natl Cancer Inst Monogr 1992; 13: 55-60.
30. Wold WS, Toth K. Chapter three - Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds. Adv Cancer Res 2012; 115: 69-92.
31. Bongers V, Braakhuis BJ, Snow GB. Circulating fragments of cytokeratin 19 in patients with head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci 1995; 20: 479-482.
32. Xu XC, Lee JS, Lippman SM, Ro JY, Hong WK, Lotan R. Increased expression of cytokeratins CK8 and CK19 is associated with head and neck carcinogenesis. Cancer Epidemiol Biomarkers Prev 1995; 4: 871-876.
33. Becker MT, Shores CG, Yu KK, Yarbrough WG. Molecular assay to detect metastatic head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004; 130: 21-27.
34. Chinnadurai G. Control of apoptosis by human adenovirus genes. Semin Virol 1998; 8: 399-408.
35. Cuconati A, White E. Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection. Genes Dev 2002; 16: 2465-2478.
36. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WS. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther 2008; 16: 1665-1673.
37. Young BA, Spencer JF, Ying B, Tollefson AE, Toth K, Wold WS. The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors. Cancer Gene Ther 2013; 20: 521-530.
38. Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004; 55: 433-457.
39. Herbst RS, Fukuoka M, Baselga J. Gefitinib - a novel targeted approach to treating cancer. Nat Rev Cancer 2004; 4: 956-965.
40. Carlin CR, Tollefson AE, Brady HA, Hoffman BL, Wold WS. Epidermal growth factor receptor is down-regulated by a 10,400 MW protein encoded by the E3 region of adenovirus. Cell 1989; 57: 135-144.
41. Tollefson AE, Stewart AR, Yei SP, Saha SK, Wold WS. The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus form a complex and function together to down-regulate the epidermal growth factor receptor. J Virol 1991; 65: 3095-3105.
42. Flinterman MB, Mymryk JS, Klanrit P, Yousef AF, Lowe SW, Caldas C et al. p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing. Oncogene 2007; 26: 6863-6874.
43. Flinterman M, Gaken J, Farzaneh F, Tavassoli M. E1A-mediated suppression of EGFR expression and induction of apoptosis in head and neck squamous carcinoma cell lines. Oncogene 2003; 22: 1965-1977.